Details for New Drug Application (NDA): 214290
✉ Email this page to a colleague
NDA 214290 describes SUGAMMADEX SODIUM, which is a drug marketed by Aspiro and Zydus Pharms and is included in two NDAs. Additional details are available on the SUGAMMADEX SODIUM profile page.
The generic ingredient in SUGAMMADEX SODIUM is sugammadex sodium. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sugammadex sodium profile page.
The generic ingredient in SUGAMMADEX SODIUM is sugammadex sodium. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sugammadex sodium profile page.
Summary for 214290
| Tradename: | SUGAMMADEX SODIUM |
| Applicant: | Zydus Pharms |
| Ingredient: | sugammadex sodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | ||||
| Approval Date: | Oct 4, 2023 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | ||||
| Approval Date: | Oct 4, 2023 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
